137 related articles for article (PubMed ID: 24740684)
1. The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study.
Mahrooz A; Parsanasab H; Hashemi-Soteh MB; Kashi Z; Bahar A; Alizadeh A; Mozayeni M
Clin Exp Med; 2015 May; 15(2):159-65. PubMed ID: 24740684
[TBL] [Abstract][Full Text] [Related]
2. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.
Umamaheswaran G; Praveen RG; Damodaran SE; Das AK; Adithan C
Clin Exp Med; 2015 Nov; 15(4):511-7. PubMed ID: 25492374
[TBL] [Abstract][Full Text] [Related]
3. The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.
Taheri R; Kazerouni F; Mirfakhraei R; Kalbasi S; Shahrokhi SZ; Rahimipour A
Gene; 2022 May; 823():146382. PubMed ID: 35240257
[TBL] [Abstract][Full Text] [Related]
4. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.
Zhou Y; Ye W; Wang Y; Jiang Z; Meng X; Xiao Q; Zhao Q; Yan J
Int J Clin Exp Pathol; 2015; 8(8):9533-42. PubMed ID: 26464716
[TBL] [Abstract][Full Text] [Related]
6. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
Kashi Z; Masoumi P; Mahrooz A; Hashemi-Soteh MB; Bahar A; Alizadeh A
Diabetes Res Clin Pract; 2015 Apr; 108(1):78-83. PubMed ID: 25662675
[TBL] [Abstract][Full Text] [Related]
7. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes.
Dujic T; Causevic A; Bego T; Malenica M; Velija-Asimi Z; Pearson ER; Semiz S
Diabet Med; 2016 Apr; 33(4):511-4. PubMed ID: 26605869
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review protocol.
Mato EPM; Guewo-Fokeng M; Faadiel Essop M; Owira PMO
Syst Rev; 2018 Jul; 7(1):105. PubMed ID: 30041690
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy.
Singh S; Shukla AK; Usman K; Banerjee M
Pharmacogenet Genomics; 2023 Apr; 33(3):51-58. PubMed ID: 36853844
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
Berstein LM; Iyevleva AG; Vasilyev D; Poroshina TE; Imyanitov EN
Cell Cycle; 2013 Dec; 12(23):3681-8. PubMed ID: 24145224
[TBL] [Abstract][Full Text] [Related]
11. Role of human organic cation transporter-1 (OCT-1/SLC22A1) in modulating the response to metformin in patients with type 2 diabetes.
Kawoosa F; Shah ZA; Masoodi SR; Amin A; Rasool R; Fazili KM; Dar AH; Lone A; Ul Bashir S
BMC Endocr Disord; 2022 May; 22(1):140. PubMed ID: 35619086
[TBL] [Abstract][Full Text] [Related]
12. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
[TBL] [Abstract][Full Text] [Related]
13. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin.
Li Q; Liu F; Zheng TS; Tang JL; Lu HJ; Jia WP
Acta Pharmacol Sin; 2010 Feb; 31(2):184-90. PubMed ID: 20139901
[TBL] [Abstract][Full Text] [Related]
14. Allele frequency and genotype distribution of a common variant in the 3´-untranslated region of the SLC22A3 gene in patients with type 2 diabetes: Association with response to metformin.
Ghaffari-Cherati M; Mahrooz A; Hashemi-Soteh MB; Hosseyni-Talei SR; Alizadeh A; Nakhaei SM
J Res Med Sci; 2016; 21():92. PubMed ID: 28163738
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
Mofo Mato EP; Guewo-Fokeng M; Essop MF; Owira PMO
Medicine (Baltimore); 2018 Jul; 97(27):e11349. PubMed ID: 29979413
[TBL] [Abstract][Full Text] [Related]
16. rs622342A>C in SLC22A1 is associated with metformin pharmacokinetics and glycemic response.
Naja K; El Shamieh S; Fakhoury R
Drug Metab Pharmacokinet; 2020 Feb; 35(1):160-164. PubMed ID: 31974043
[TBL] [Abstract][Full Text] [Related]
17. Association between the synonymous variant organic cation transporter 3 (OCT3)-1233G>A and the glycemic response following metformin therapy in patients with type 2 diabetes.
Hosseyni-Talei SR; Mahrooz A; Hashemi-Soteh MB; Ghaffari-Cherati M; Alizadeh A
Iran J Basic Med Sci; 2017 Mar; 20(3):250-255. PubMed ID: 28392895
[TBL] [Abstract][Full Text] [Related]
18. A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT.
Out M; Becker ML; van Schaik RH; Lehert P; Stehouwer CD; Kooy A
Pharmacogenomics; 2018 Jun; 19(8):715-726. PubMed ID: 29790415
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.
Chen L; Takizawa M; Chen E; Schlessinger A; Segenthelar J; Choi JH; Sali A; Kubo M; Nakamura S; Iwamoto Y; Iwasaki N; Giacomini KM
J Pharmacol Exp Ther; 2010 Oct; 335(1):42-50. PubMed ID: 20639304
[TBL] [Abstract][Full Text] [Related]
20. Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients.
Shokri F; Ghaedi H; Ghafouri Fard S; Movafagh A; Abediankenari S; Mahrooz A; Kashi Z; Omrani MD
Int J Mol Cell Med; 2016; 5(1):1-7. PubMed ID: 27386433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
